Your session is about to expire
← Back to Search
Other
Tailored Regimen for Hemophilia A (PMCH Trial)
N/A
Recruiting
Led By Alfonso Iorio, MD, PhD, FRCPC
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at study enrollment and at 2 years at study completion.
Awards & highlights
No Placebo-Only Group
Summary
This trial will assess the impact of adopting population PK (popPK) based tailored prophylaxis in clinical practice, including proportion of patients eligible for tailoring, and encountered barriers.
Eligible Conditions
- Hemophilia A
- Hemophilia B
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured at study enrollment and at 2 years at study completion.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at study enrollment and at 2 years at study completion.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Annualized Bleeding Rate (ABR) pre and post-tailoring implementation
Change in patient quality of life
Secondary study objectives
Adherence to prescribed regimen
Assessment of the predictive performance of the WAPPS-Hemo clinical calculator
Change in joint function
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tailored RegimenExperimental Treatment1 Intervention
Implementation of WAPPS-Hemo personalized dosing regimen.
Find a Location
Who is running the clinical trial?
McMaster UniversityLead Sponsor
916 Previous Clinical Trials
2,614,628 Total Patients Enrolled
2 Trials studying Hemophilia A
1,400 Patients Enrolled for Hemophilia A
Alfonso Iorio, MD, PhD, FRCPCPrincipal InvestigatorMcMaster University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are taking a medication to prevent bleeding episodes.You have a bleeding disorder that is not Hemophilia A or B.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Tailored Regimen
Share this study with friends
Copy Link
Messenger